January 28, 2021
Fujimoto Pharmaceutical’s Thaled (thalidomide) cleared a key health ministry advisory panel on January 27 for its label expansion into POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, putting itself in line for approval as early as next month. The...read more